Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for statements about deals, orders, contracts, projects, customers, sites, or programs being individually bigger, broader, or longer than before. Scan transcript for such language. Bobby mentions new products, but specifically about deals: "we’ve recently begun to market and sale some of those products... all six products have shown revenue and some sales orders in this quarter" - not about size. He mentions a large customer: "one of our largest customers in our entire customer base, selected our OB Risk program... for system-wide deployment in a multiyear agreement" - that's a large deal, but is it part of an upward drift? He also says "that same account... renewed its enterprise-wide use of our core platform and it's an early renewal, about a one year early renewal and they added four years to that early year. So it's essentially a five year contract." That's a large contract, but is it described as part of a trend? He says "there’s lot of exciting pieces to that part of equation as we move one of our largest accounts on our newer technologies." Not clearly a trend of escalating size. Later, about resuscitation: "we’ve signed two new strategic partners in the last 100 days" - that's about partners, not deals. He talks about new products like Nurse Residency Pathway, but not about deal size escalation. Gerry mentions "a one-time adjustment led to a few customer contracts" and "organic growth" but not about size. No explicit statement that deals are getting larger. The large OB Risk deal is presented as a single event, not as part of a pattern. Also, he says "we’ve seen some early preliminary indications of success" but not about size. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.